Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis.

ABSTRACT:

Background

Experience with immune checkpoint inhibitors (ICIs) in the treatment of acute myeloid leukemia (AML) is still limited and based on early clinical trials, with no reported randomized clinical data. In this study, we reviewed the available evidence on the use of ICIs, either in monotherapy or in combination with other treatments, in different AML settings, including newly diagnosed AML, relapsed or refractory (R/R) AML and maintenance treatment after allogeneic-HSCT (allo-HSCT).

Materials and methods

A systematic literature review was conducted using PubMed electronic database as primary source to identify the studies involving immune checkpoint inhibitors in first-line and R/R AML. We recorded Overall Response (ORR), Complete Response (CR) and Complete Response wit

SUBMITTER: Gomez-Llobell M 

PROVIDER: S-EPMC9069679 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature